This represents an important finding that has the potential to refine the utility of WGMA to predict the IDH1/IDH2 mutation status of gliomas, thus improving diagnostic yield and efficiency of laboratory testing compared to single analyte IDH1/IDH2 tests. This evidence concerns the gene IDH2 and central nervous system cancer.